Hanall Biopharma Rises 5.73% Amid Immune Checkpoint Inhibitor Theme Uptrend

On the 10th, the immuno-oncology theme rose 3.09% compared to the previous day, showing strength, while HanAll Biopharma, a related stock drawing attention, surged 5.73% compared to the previous day. HanAll Biopharma is known as an R&D-focused pharmaceutical bio company.

[Graph] Major stock price changes in the immuno-oncology theme



According to provisional data compiled at 10:26, foreigners sold 35,800 shares of HanAll Biopharma, resulting in a large net sell-off by foreign investors.

[Table] Net trading volume of foreigners and institutions (unit: 10,000 shares)



According to the analysis by Thinkpool Robo Algorithm RASSI, HanAll Biopharma exceeded the theme's average scores in growth, stability, and profitability, ranking 2nd in quant financial ranking (out of 25 stocks). This can be interpreted as HanAll Biopharma having relatively high investment attractiveness compared to other stocks in the theme from a financial perspective.

[Table] Top stocks by financial score within the theme


※ The quant financial score is the result of the robo algorithm analyzing each company's sales growth rate, equity growth rate, debt ratio, current ratio, ROA, ROE, etc.

※ This article was generated in real-time by an article auto-generation algorithm jointly developed by Asia Economy and the financial AI specialist Thinkpool.